Moderna
Search results
BioNTech. We are a global immunotherapy powerhouse aspiring to translate science into survival. Read more. Interest Selector. Our mission. We are committed to improving the health of people worldwide with our fundamental research and development of immunotherapies. We believe in scientific rigor, innovation and passion as driving force.
BioNTech SE ( / biːˈɒntɛk / bee-ON-tek; or / baɪˈɒntɛk / bye-ON-tek [2] short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
BioNTech is a fully integrated, global immunotherapy powerhouse. We have been working on automated and digitized processes and build continuously capabilities for specialized manufacturing, either for individualized vaccines or for large-scale products like our COVID-19 vaccine.
A transatlantic leader in individualized neoantigen-targeted T cell therapies. Based in Cambridge, MA, BioNTech US serves as BioNTech’s North American headquarters and is an important part of our global effort to pioneer the development of next-generation immuno-oncology therapies.
May 22, 2024 · Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.
Aug 18, 2022 · This article provides a summary of the interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19 issued by WHO Strategic Advisory Group of Experts on Immunization (SAGE).
BioNTech, a German immunotherapy company, had pioneered a new genetic technology that uses a wisp of genetic code from a virus—called messenger RNA—to prompt cells to make antibodies that fight off that virus 4.
Oct 15, 2021 · BioNTech, a German immunotherapy company, had pioneered a new genetic technology that uses a wisp of genetic code from a virus—called messenger RNA—to prompt cells to make antibodies that fight off that virus. 4 For decades, scientists had been working on similar concepts but frequently met defeat because of issues related to the structure ...
Apr 9, 2020 · BioNTech will receive an upfront payment of $185 million, including an equity investment of approximately $113 million, and be eligible to receive future milestone payments of up to $563 million for a potential total consideration of $748 million.
Nov 13, 2020 · A vaccine candidate developed by the company they co-founded 12 years ago, BioNTech, was more than 90 per cent effective in preventing the disease — a far higher level than the widely-used jabs...
